HLN
Strong BuyFull HouseAI neutralHaleon plc · Healthcare · United Kingdom · $45.2B cap · $204.3M/day traded
$10.27 -1.0% · close 23 Oct · scored 24 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
As of 24 Oct 2026, MoatMap's StockRank for Haleon plc (HLN) is 80/100, ranked against 24,000+ stocks in 35 markets (Quality 61, Value 60, Momentum 55, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Haleon owns strong consumer health brands such as Sensodyne, Advil, Centrum and Panadol, with durable pricing power and solid cash generation. The business quality is real. However, JPMorgan turned more cautious on growth, and analysts expect the company to cut its sales growth guidance on a weak cough and cold season. Forward earnings estimates fell 2% over about four weeks. Without an acceleration catalyst, it looks like a steady, fairly valued compounder rather than a mispriced opportunity.
ABOUT HALEON PLC
Read
Haleon plc is the world's largest pure-play consumer healthcare company, boasting a portfolio of category-leading brands such as Sensodyne, Advil, and Centrum. Spun off from GSK and Pfizer, the company possesses a powerful competitive moat built on deep clinical heritage, strong brand equity, and extensive global retail distribution. It operates as a highly defensive, cash-generative business well-positioned to benefit from secular trends in self-care and aging demographics.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 14.5B | 15.1B | 15.0B | 14.7B | 0.5% | 14.9B | 15.2B | 15.8B | 3.7% |
| EPS | — | 0.64 | 0.64 | 0.87 | 1.00 | 16.0% | 0.49 | 1.11 | 1.22 | 10.1% |
| Shares | — | 4.4B | 4.4B | 4.4B | 4.4B | 0.0% | 4.4B | — | — | — |
| Debt | — | 13.9B | 12.6B | 13.5B | 11.5B | -6.3% | 11.0B | — | — | — |
| Equity | — | 21.8B | 22.2B | 21.6B | 21.9B | 0.2% | — | — | — | — |
| Op CF | 1.8B | 2.8B | 2.8B | 3.1B | 3.5B | 18.1% | 3.5B | — | — | — |
| Inv CF | -44.1M | -11.7B | -178.9M | 704.9M | -461.9M | — | — | — | — | — |
| Fin CF | -1.7B | 9.2B | -2.1B | -2.1B | -4.2B | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Calmer than 86% of stocks we rank over the past year (23% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HLN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HLN | Haleon plc(you) | $45.2B | 80 | Strong Buy |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.0B | 79 | Buy |
| HIK.L | Hikma Pharmaceuticals PLC | $4.6B | 93 | Strong Buy |
| GSK | GSK plc | $101.7B | 83 | Strong Buy |
| SN.L | Smith & Nephew plc | $12.9B | 87 | Strong Buy |
| EAH.L | ECO Animal Health Group plc | $85M | 89 | Strong Buy |
| AZN.ST | AstraZeneca PLC | $264.5B | 79 | Buy |
| CTEC.L | Convatec Group PLC | $6.3B | 78 | Buy |
| LIVN | LivaNova PLC | $4.4B | 85 | Strong Buy |
| ROIV | Roivant Sciences Ltd. | $26.4B | 23 | Sell |
Peer medians: ROE -6.4% · P/E 25.0x · Gross margin 54.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.